Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer and BioNTech announce the FDA's Emergency Use Authorization (EUA) for their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a third 3-µg dose in the primary vaccination series for children aged 6 months to 4 years. Given the urgent need due to rising COVID-19 cases and respiratory illnesses in young children, vaccine doses will ship immediately upon CDC recommendation. The EUA is supported by clinical data and aims to enhance protection against severe illness in this age group.
Pfizer (NYSE: PFE) announced that the FDA has accepted its Biologics License Application (BLA) for RSV vaccine candidate RSVpreF for individuals aged 60 and older. The priority review status shortens the review process by four months, aiming for a decision by May 2023. This follows the FDA's Breakthrough Therapy Designation granted in March 2022. RSV causes significant morbidity among older adults, with 60,000-120,000 hospitalizations annually in the U.S. The vaccine candidate is supported by a Phase 3 trial involving approximately 37,000 participants, showing promise in addressing this public health challenge.
Pfizer (NYSE: PFE) announced a collaboration with Clear Creek Bio to develop novel papain-like protease (PLpro) inhibitors aimed at treating COVID-19. This partnership will enhance Pfizer's existing COVID-19 product line with potential oral antivirals targeting various viral mechanisms. Both companies will work on identifying a PLpro candidate for clinical development, with Pfizer taking charge of commercialization. Clear Creek will receive an undisclosed upfront payment and potential future royalties based on product sales.
Pfizer Inc. (NYSE: PFE) invites investors to its Near-Term Launches + High-Value Pipeline Day on December 12, 2022, from 1:00 p.m. EST to 6:00 p.m. EST. The event will showcase potential product launches and pipeline programs that are expected to drive revenue growth through 2030. The live video webcast will be accessible via Pfizer's investor website, with an opportunity for audience questions during the Q&A sessions. A transcript and replay of the event will be available online within 24 hours.
On World AIDS Day, the Health Action Alliance and ViiV Healthcare launched the U.S. Business Action to End HIV, a coalition of businesses aimed at eliminating HIV in the U.S. by 2030. Founding members include major companies like CVS Health, Gilead Sciences, and Walgreens. The initiative aligns with the National HIV/AIDS Strategy and seeks to mobilize private sector support to improve access to HIV prevention and treatment. More than 1.2 million people in the U.S. live with HIV, with nearly 35,000 new cases annually.
ViiV Healthcare released survey data on World AIDS Day 2022, highlighting persistent stigma surrounding HIV. Conducted by Opinium, the survey revealed that 74% of respondents believe negative perceptions still exist, with 25% opposing discussions about HIV in workplaces. While 76% feel comfortable with physical contact with those living with HIV, only 50% would date someone with the virus. The campaign, ‘HIV in View’, aims to combat stigma through public awareness and advocacy for non-stigmatising language.
Pfizer Inc. (NYSE: PFE) invites investors and the public to join a webcast featuring CFO David Denton at the Wolfe Research Healthcare Conference on November 18, 2022, at 8:45 a.m. EST. Investors can access the webcast at www.pfizer.com/investors, where information on registration will also be available. A transcript and replay will be accessible on Pfizer's site within 24 hours post-event for at least 90 days. Pfizer focuses on innovative therapies, improving patients' lives, and enhancing healthcare access globally.
Pfizer and BioNTech announced robust results from a Phase 2/3 clinical trial for their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. A 30-µg booster significantly increased neutralizing antibody titers—13.2-fold in adults over 55 and 9.5-fold for those aged 18 to 55 compared to the original vaccine. The safety profile remains favorable, similar to the original vaccine. These findings suggest enhanced protection against Omicron variants and support ongoing evaluations of the vaccine's effectiveness against emerging strains.
Pfizer's investigational cancer immunotherapy, elranatamab, has received Breakthrough Therapy Designation from the FDA for treating relapsed or refractory multiple myeloma (RRMM). This designation is based on promising results from the Phase 2 MagnetisMM-3 study, which reported a 61% overall response rate after a median follow-up of 6.8 months. The therapy could provide significant advantages over existing treatments.
Elranatamab is designed to engage cancer and T-cells simultaneously, offering a novel approach to treatment.
Transgene (Euronext Paris: TNG) announces that an interim analysis of its Phase II clinical trial for TG4001 has shown promising results, leading the Independent Data Monitoring Committee to recommend continuation. The trial will now enroll 120 patients instead of the previously planned 150, with a completion expected in H1 2024. TG4001, a therapeutic vaccine for HPV16-positive anogenital tumors, is being tested in combination with avelumab, supplied by Pfizer (NYSE: PFE). A webcast on the interim results is scheduled for November 2, 2022.